Patent intelligence · US
US 11566032
Radio-protective and chemo-protective substituted thiols
Radio-protective and chemo-protective substituted thiols
Patent details — US 11566032
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2023
- Expiration
- Jan 26, 2043
- Applicant
- TONIX PHARMACEUTICALS HOLDING CORP
- Claims
- 25
- CPC classes
- A61K, A61K31/145, A61K31/495, A61K31/498
Quick answer
US 11566032 (Radio-protective and chemo-protective substituted thiols) is held by TONIX PHARMACEUTICALS HOLDING CORP. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TONIX PHARMACEUTICALS HOLDING CORP
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/145, A61K31/495, A61K31/498, A61K31/4985, A61K31/551
More from TONIX PHARMACEUTICALS HOLDING CORP
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 11566032?
US 11566032 (Radio-protective and chemo-protective substituted thiols) is held by TONIX PHARMACEUTICALS HOLDING CORP. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11566032?
TONIX PHARMACEUTICALS HOLDING CORP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 11566032 expire?
Our index shows an expiration date of Jan 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.